Literature DB >> 21751052

Use of prescription drug samples and patient assistance programs, and the role of doctor-patient communication.

Walid F Gellad1, Haiden A Huskamp, Angela Li, Yuting Zhang, Dana Gelb Safran, Julie M Donohue.   

Abstract

BACKGROUND: Cost-related underuse of medications is common among older adults, who seldom discuss medication costs with their physicians. Some older adults may use free drug samples or industry-sponsored patient assistance programs (PAP) in hopes of lowering out-of-pocket costs, although the long-term effect of these programs on drug spending is unclear.
OBJECTIVE: To examine older adults' use of industry-sponsored strategies to reduce out-of-pocket drug costs and the association between doctor-patient communication and use of these programs.
DESIGN: Cross-sectional analysis of a 2006 nationally representative survey of Medicare beneficiaries. PARTICIPANTS: 14,322 community-dwelling Medicare beneficiaries age ≥65. MAIN MEASURES: We conducted bivariate and multivariate analyses of the association between receipt of free samples and participation in PAPs with sociodemographic characteristics, health status, access to care, drug coverage, medication cost burden, and doctor-patient communication. KEY
RESULTS: 51.4% of seniors reported receiving at least one free sample over the last 12 months and 29.2% reported receiving free samples more than once. In contrast, only 1.3% of seniors reported participating in an industry-sponsored PAP. Higher income respondents were more likely to report free sample receipt than low-income respondents (50.8% vs. 43.8%, p < 0.001) and less likely to report participating in a PAP (0.42% vs. 2.2%, p < 0.001). In multivariate analyses, those who reported talking to their doctor about the cost of their medications had more than twice the odds of receiving samples as those who did not (OR 2.17, 95% CI 1.95-2.42).
CONCLUSIONS: In 2006, over half of seniors in Medicare received free samples, but only 1.3% reported receiving any medications from a patient assistance program. Doctor-patient communication is strongly associated with use of these programs, which has important implications for clinical care regardless of whether these programs are viewed as drivers of prescription costs or a remedy for them.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21751052      PMCID: PMC3235606          DOI: 10.1007/s11606-011-1801-y

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  33 in total

1.  Pharmaceutical manufacturer assistance programs for indigent patients: solution or symptom?

Authors:  L R Van Diepen
Journal:  Am J Health Syst Pharm       Date:  2001-01-15       Impact factor: 2.637

2.  Pharmaceutical manufacturer prescription assistance programs: are they worth it?

Authors:  Judy T Chen; Kent H Summers
Journal:  J Manag Care Pharm       Date:  2007-09

3.  Asking questions about medication: analysis of physician-patient interactions and physician perceptions.

Authors:  B Sleath; D Roter; B Chewning; B Svarstad
Journal:  Med Care       Date:  1999-11       Impact factor: 2.983

4.  Physician strategies to reduce patients' out-of-pocket prescription costs.

Authors:  G Caleb Alexander; Lawrence P Casalino; David O Meltzer
Journal:  Arch Intern Med       Date:  2005-03-28

5.  A physician survey of the effect of drug sample availability on physicians' behavior.

Authors:  L D Chew; T S O'Young; T K Hazlet; K A Bradley; C Maynard; D S Lessler
Journal:  J Gen Intern Med       Date:  2000-07       Impact factor: 5.128

6.  The effects of the coverage gap on drug spending: a closer look at Medicare Part D.

Authors:  Yuting Zhang; Julie Marie Donohue; Joseph P Newhouse; Judith R Lave
Journal:  Health Aff (Millwood)       Date:  2009-02-03       Impact factor: 6.301

7.  Free drug samples in the United States: characteristics of pediatric recipients and safety concerns.

Authors:  Sarah L Cutrona; Steffie Woolhandler; Karen E Lasser; David H Bor; David U Himmelstein; William H Shrank; Neal S LeLeiko
Journal:  Pediatrics       Date:  2008-10       Impact factor: 7.124

8.  Characteristics of recipients of free prescription drug samples: a nationally representative analysis.

Authors:  Sarah L Cutrona; Steffie Woolhandler; Karen E Lasser; David H Bor; Danny McCormick; David U Himmelstein
Journal:  Am J Public Health       Date:  2008-01-02       Impact factor: 9.308

9.  Cost-related medication nonadherence among beneficiaries with depression following Medicare Part D.

Authors:  Kara Zivin; Jeanne M Madden; Amy J Graves; Fang Zhang; Stephen B Soumerai
Journal:  Am J Geriatr Psychiatry       Date:  2009-12       Impact factor: 4.105

10.  No more free drug samples?

Authors:  Susan Chimonas; Jerome P Kassirer
Journal:  PLoS Med       Date:  2009-05-12       Impact factor: 11.069

View more
  12 in total

1.  Utilization of free medication samples in the United States in a nationally representative sample: 2009-2013.

Authors:  Joshua D Brown; Pratik A Doshi; Jeffery C Talbert
Journal:  Res Social Adm Pharm       Date:  2016-01-30

2.  Physician-patient communication on cost and affordability in asthma care. Who wants to talk about it and who is actually doing it.

Authors:  Minal R Patel; John R C Wheeler
Journal:  Ann Am Thorac Soc       Date:  2014-12

3.  Impact of rural residence on forgoing healthcare after cancer because of cost.

Authors:  Nynikka R A Palmer; Ann M Geiger; Lingyi Lu; L Douglas Case; Kathryn E Weaver
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10       Impact factor: 4.254

4.  Treatment differences by health insurance among outpatients with coronary artery disease: insights from the national cardiovascular data registry.

Authors:  Kim G Smolderen; John A Spertus; Fengming Tang; William Oetgen; William B Borden; Henry H Ting; Paul S Chan
Journal:  J Am Coll Cardiol       Date:  2013-01-30       Impact factor: 24.094

5.  How quickly do physicians adopt new drugs? The case of second-generation antipsychotics.

Authors:  Haiden A Huskamp; A James O'Malley; Marcela Horvitz-Lennon; Anna Levine Taub; Ernst R Berndt; Julie M Donohue
Journal:  Psychiatr Serv       Date:  2013-04-01       Impact factor: 3.084

6.  Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology.

Authors:  Christian Hampp; Patty Greene; Simone P Pinheiro
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

7.  Who Were the Early Adopters of Dabigatran?: An Application of Group-based Trajectory Models.

Authors:  Wei-Hsuan Lo-Ciganic; Walid F Gellad; Haiden A Huskamp; Niteesh K Choudhry; Chung-Chou H Chang; Ruoxin Zhang; Bobby L Jones; Hasan Guclu; Seth Richards-Shubik; Julie M Donohue
Journal:  Med Care       Date:  2016-07       Impact factor: 2.983

8.  Pharmaceutical Cost-Saving Strategies and their Association with Medication Adherence in a Medicare Supplement Population.

Authors:  Shirley Musich; Yan Cheng; Shaohung S Wang; Cynthia E Hommer; Kevin Hawkins; Charlotte S Yeh
Journal:  J Gen Intern Med       Date:  2015-02-10       Impact factor: 5.128

9.  Patient Assistance Programs and Technology in Medication Adherence.

Authors:  Carlos Colon; Paulette Salas; Militza Díaz; Raiza Cotto; Isabel Martínez; Genevieve M Hale; Nile M Khanfar
Journal:  Innov Pharm       Date:  2020-04-30

10.  Patient-physician discussions about costs: definitions and impact on cost conversation incidence estimates.

Authors:  Wynn G Hunter; Ashley Hesson; J Kelly Davis; Christine Kirby; Lillie D Williamson; Jamison A Barnett; Peter A Ubel
Journal:  BMC Health Serv Res       Date:  2016-03-31       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.